《大行》大摩:中国生物科技股第四季催化剂前瞻 行业评级“吸引”

阿斯达克财经
Yesterday

摩根士丹利就中国生物科技股发表研究报告,识别并预览可能于2026年第四季影响行业股价的潜在催化剂,行业评级为“吸引”。该行指出,康方生物(09926.HK) 方面,预期HARMONi-3无进展生存期(PFS)效益或轻微减弱,但西方患者停药及对照组使用pembrolizumab或带来总生存期(OS)风险;两名美国KOL希望OS风险比达0.70至0.75,另一人则认为0.78至0.80已具意义。和誉-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10